ClinicalTrials.gg
RecruitingNCT05908227MASTERUpdated Feb 21, 2025

Effects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm Infants

An interventional study of NHF high and NHF low in Respiratory Distress Syndrome, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 2 sites in 2 countries. Open to participants aged 23 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
23 Weeks to 31 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.

Planned enrollment
10th of 26
150 · median 114
Started
2023
with 1 other
No phase
13 of 48
3 open now
Registered
47th of 48
by date

Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, and was the 47th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 23 Weeks to 31 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Respiratory Distress Syndrome with a site in Germany, or all of them as a file.
02

Study summary

Premature babies often need help breathing for a longer period of time. Traditionally, this is done with a breathing aid called NCPAP (nasal continuous positive airway pressure). This treatment is safe and effective, but it is very time-consuming and can sometimes have side effects. In the present research project, the investigators want to find out whether another type of breathing aid called NHF (nasal high flow therapy) is just as effective for stable premature babies. The investigators suspect that NHF is just as effective, but easier to use and more comfortable.

Read the detailed description

This is a multi center parallel group three arm randomized controlled clinical trial investigating cardiorespiratory stability in stable preterm infants receiving NHF.

Currently, NCPAP remains the gold standard for administration of prolonged non-invasive ventilatory support in very preterm infants. NHF is a promising method for tailored, less invasive long-term ventilatory support for preterm infants. If ventilatory support with NHF is similarly effective to conventional NCPAP in stable preterm infants, clinicians are likely to adopt this method for widespread clinical use because of its improved comfort and potential other benefits. Primary aim of this trial is to examine cardiorespiratory stability in preterm infants treated with two commonly used NHF flowrates (Interventional group 1 and 2) in comparison to NCPAP (Comparator). Secondary aim is to examine potential comfort-related beneficial effects of NHF.

03

Conditions studied

  • Respiratory Distress Syndrome

Keywords

  • Nasal high flow therapy
  • Continuous positive airway pressure
04

Who can participate

Ages eligible
23 Weeks to 31 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion if all apply.

  • Preterm infants up to 31+6 weeks GA admitted to the Division of Neonatology at Inselspital Bern, Switzerland or Division of Neonatology at the University Medical Center of the Johannes Gutenberg-University Mainz, Germany (inborn or outborn)
  • >2nd day of life (defined as date day)
  • Stable on NCPAP 6 cm H2O for ≥ 24 hours, defined as:

    • ≤ 2 apneas with concomitant bradycardias (\<100/min) per hour for the previous 6 hours
    • FiO2 ≤ 0.3 and not increasing
    • No significant chest recessions (Silverman Score \< 5)
    • Respiratory rate ≤ 60/min
    • No need for intermittent positive pressure ventilation
  • Parents with an age 18+ years
  • Written parental (or other legal representative)

Exclusion Criteria:

Exclusion if any applies.

  • Significant fetal anomalies
  • Primary palliative care
  • Stable on NCPAP 6 cm H2O according to stability criteria for more than 120 hours
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NHF high

    Nasal high flow therapy 8L/min

    Other: NHF high

  • Experimental
    NHF low

    Nasal high flow therapy 6L/min

    Other: NHF low

  • Active comparator
    NCPAP

    Nasal continuous positive airway pressure 6 cm H20

    Other: NCPAP

Interventions

  • OtherNHF high

    Nasal high flow therapy 8L/min.

  • OtherNHF low

    Nasal high flow therapy 6L/min.

  • OtherNCPAP

    Nasal continuous positive airway pressure 6 cm H20

06

What researchers measure

Primary outcomes

  1. Treatment failure

    Treatment failure is a composite outcome defined as meeting one of the following treatment failure criteria within 24 hours of starting of intervention: 1. \>2 apneas with concomitant bradycardias (\<100/min) per hour for \> 1 hour or 2. FiO2 \> 0.3 consistently for \> 1 hour or 3. Significant chest recessions (Silverman Score ≥ 5) for \> 1 hour or 4. Respiratory rate \> 60/min consistently for \> 1 hour or 5. Any need for intermittent positive pressure ventilation The presence of "Treatment failure" within 24 hours of starting of intervention will be documented (dichotomous outcome; yes/no).

    Time frame: 24 hours

Secondary outcomes

  1. Apneas and bradycardias

    The total frequency of apneas and bradycardias (\<100/min) within 24 hours of starting of intervention will be documented.

    Time frame: 24 hours

  2. Respiratory rate (RR)

    The mean RR within 24 hours of starting of intervention will be documented.

    Time frame: 24 hours

  3. Heart rate (HR)

    The mean HR within 24 hours of starting of intervention will be documented.

    Time frame: 24 hours

  4. Oxygen saturation (SpO2) and fraction of inspired oxygen (FiO2)

    The mean SpO2/FiO2 ratio within 24 hours of starting of intervention will be documented.

    Time frame: 24 hours

  5. Frequency of any treatment failure

    Treatment failure is a composite outcome (see "Outcome 1"). The frequency of any treatment failure during the duration of the study will be documented.

    Time frame: Individual study duration: estimated to be between a minimum of 7 days to an (estimated) maximum of 10 weeks.

  6. Rescue NCPAP

    Rescue NCPAP is defined as NCPAP \>6 cm H2O. The frequency of need for Rescue NCPAP during the duration of the study will be collected.

    Time frame: Individual study duration: estimated to be between 7 days to 10 weeks.

  7. Postmenstrual age (PMA) off positive pressure support

    The investigators will document the PMA when the infant is off positive pressure support.

    Time frame: Estimated to be at a PMA of approximately 29 to 34 weeks.

  8. Postmenstrual age (PMA) off FiO2 > 0.21

    The investigators will document the PMA when the infant is off FiO2 \> 0.21

    Time frame: Estimated to be at a PMA between approximately 28 to 34 weeks.

  9. Postmenstrual age (PMA) at discharge

    The investigators will document the PMA when the infant is being discharged from the hospital.

    Time frame: Estimated to be at a PMA of approximately 38-40 weeks.

  10. Cerebral oxygen saturation (cRSO2) 1 hour before until 3 hours after start of the intervention

    The cerebral oxygen saturation (cRSO2) in \[%\] 1 hour before until 3 hours after start of the intervention will be measured by using Near-infrared spectroscopy (NIRS).

    Time frame: 4 hours

  11. Time spent <55% cRSO2 1 hour before until 3 hours after start of the intervention

    The time spent \<55% cRSO2 in \[min\] 1 hour before until 3 hours after start of the intervention will be measured by using Near-infrared spectroscopy (NIRS).

    Time frame: 4 hours

  12. Cerebral oxygen saturation (cRSO2) 1 hour before until 3 hours after cessation of the intervention

    The cerebral oxygen saturation (cRSO2) in \[%\] 1 hour before until 3 hours after cessation of the intervention will be measured by using Near-infrared spectroscopy (NIRS).

    Time frame: 4 hours

  13. Time spent <55% cRSO2 1 hour before until 3 hours after cessation of the intervention

    The time spent \<55% cRSO2 in \[min\] 1 hour before until 3 hours after cessation of the intervention will be measured by using Near-infrared spectroscopy (NIRS).

    Time frame: 4 hours

  14. Change in end-expiratory lung impedance (ΔEELI)

    The change Δ in end-expiratory lung impedance (ΔEELI) will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention

    Time frame: 48 hours

  15. Change in global inhomogeneity (ΔGI) index

    The change Δ in global inhomogeneity (ΔGI) index will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention

    Time frame: 48 hours

  16. Change in variability of tidal volume (ΔTV)

    The change Δ in variability of tidal volume (ΔTV) will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention

    Time frame: 48 hours

  17. Change in ratio of tidal volume anterior/posterior (ΔRatio TV ap)

    The change Δ in ratio of tidal volume anterior/posterior (ΔRatio TV ap) will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention

    Time frame: 48 hours

  18. Incidence of Bronchopulmonary dysplasia (BPD)

    The incidence with specification of severity of BPD at 36 weeks PMA will be documented. BPD is a form of chronic lung disease (CLD). BPD is classified into 3 levels of severity according to the internationally used definition of Jobe and Bancalari (1). FiO2 \>0.21 for ≥ 28 days and 1. Breathing room air (mild) 2. FiO2 \<0.3 (moderate) 3. FiO2 ≥ 0.3 and/or positive pressure support (severe) (1) Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-9.

    Time frame: At 36 weeks PMA

  19. Urinary cortisol

    A 24-hour-urine-sample will be collected on the third study day. The urinary production rates of cortisol and the most important metabolites will be documented as an indicator for infant stress.

    Time frame: 24 hours

  20. COMFORTneo score

    The COMFORTneo score will be documented on the third, fourth and fifth study day. The score measures comfort and chronic pain by observation.

    Time frame: 72 hours

  21. Revised Bernese Pain Scale for Neonates (BSN-R) score

    The BSN-R score will be documented on the third, fourth and fifth study day. The score measures pain.

    Time frame: 72 hours

  22. Parental assessment of comfort

    The parents will be asked 3 predefined questions concerning their infants' comfort on the on the third, fourth and fifth study day.

    Time frame: 72 hours

  23. NASA Task Load Index (NASA-TLX)

    The NASA-TLX will be filled out by the participants' nurses on the third, fourth and fifth study day. The NASA-TLX is a questionnaire that measures workload.

    Time frame: 72 hours

  24. Nasal trauma score

    The nasal trauma score is assessed according to internal standard guidelines in case of a present nasal trauma. The highest respective score and time of assessment will be documented on the participant CRF at 36 weeks PMA. Measuring nasal trauma using the Nasal trauma score takes approximately 20 seconds.

    Time frame: Individual study duration: estimated to be between 7 days to 10 weeks.

  25. Behavioral Sleep stage classification for Preterm Infants (BeSSPI)

    Sleep-wake cycles as determined by the BeSSPI on the fourth study day will be documented. The BeSSPI identifies sleep stages by observation and takes approximately 2.5 hours.

    Time frame: 24 hours

  26. Parental Bonding Questionnaire (PBQ)

    The score of the PBQ will be documented at 36 weeks PMA. The PBQ investigates infant-parental bonding.

    Time frame: At 36 weeks PMA

  27. Age at initiating breastfeeds

    The postmenstrual age (PMA) at initiating breastfeeds will be documented. This refers to the PMA at which the first successful breastfeeding attempt takes place.

    Time frame: Estimated to be between 30-34 weeks PMA.

  28. Age at reaching full breastfeeds

    The postmenstrual age (PMA) at reaching full breastfeeds will be documented. This corresponds to 100% nutrition per breastfeeds for 24 consecutive hours.

    Time frame: Estimated to be between 34-40 weeks PMA.

  29. Weight

    The weight in \[g\] at 36 weeks postmenstrual age (PMA) will be documented.

    Time frame: At 36 weeks PMA

  30. Head circumference

    The head circumference in \[cm\] at 36 weeks postmenstrual age (PMA) will be documented.

    Time frame: At 36 weeks PMA

07

Study locations

2 of 2 sites recruiting
  • University Medical Center of the Johannes Gutenberg-University Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
    Recruiting
  • Department of Pediatrics, Inselspital
    Bern, 3010, Switzerland
    Recruiting
    • Lisa M Bünte · Contactlisamarie.buente@insel.ch · +41316321923
    • André Kidszun, Prof. Dr. med. · Contactandre.kidszun@insel.ch · +41 31 632 14 01
    • André Kidszun, Prof. Dr. med. · Principal investigator
    • Lisa M Bünte · Sub investigator
    • Thomas Riedel, Prof. Dr. med. · Sub investigator
    • Thomas Riva, Prof. Dr. med. · Sub investigator
    • Bubl Benedikt, Dr. med. · Sub investigator
08

References and documents

Publications

  • Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9. doi: 10.1164/ajrccm.163.7.2011060. No abstract available. PubMed 11401896 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 29 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2023
First posted
Jun 18, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Feb 2026
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05908227
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jul 1, 2023
Primary completion
Dec 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Feb 21, 2025

Study contacts

Lisa Marie Bünte
Contact
lisamarie.buente@insel.ch
+41 31 632 19 23
André Kidszun, Prof. Dr. med.
Contact
andre.kidszun@insel.ch
+41 31 632 14 01
André Kidszun, Prof. Dr. med.
principal investigator · Division of Neonatology, Department of Pediatrics, Inselspital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion